Manufacturer record
Indus Pharma Pvt. Ltd: regulatory record
Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
6 batches manufactured by Indus Pharma Pvt. Ltd (Rajasthan) were declared Not of Standard Quality between May 2025 and July 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Records by type
6 records linked to Indus Pharma Pvt. Ltd in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Buprenorphine Injection IP. 2ml | BUP324040Mfg 2024-12 · Exp 2026-07 | The sample does not conform to I.P. with respect to tests of Particulate matter and Assay of Buprenorphine.Assay | CDL, KolkataCDSCO lab | Jul 2026 |
| Buprenorphine Injection IP 2ml | BUP325007Mfg 2025-09 · Exp 2027-08 | The sample does not conform to I.P. with respect to the test of Particulate Matter and for the reason stated under Description.Description | CDL, KolkataCDSCO lab | Apr 2026 |
| Buprenorphine Injection IP 2ml | BUP325004Mfg 2025-04 · Exp 2027-03 | The sample does not conform to I.P. with respect to the Tests of Extractable volume, Particulate matter and for the reason stated under Description.Description | CDL, KolkataCDSCO lab | Jan 2026 |
| Buprenorphine Injection IP 2ml | BUP325004Mfg 2025-04 · Exp 2027-03 | The sample does not conform I.P. with respect to the Test of Particulate matter and for the reason stated under Description.Description | CDL, KolkataCDSCO lab | Jan 2026 |
| Buprenorphine Injection IP 2ml | BUP325005Mfg 2025-05 · Exp 2027-04 | The sample does not conform to I.P. with respect to the Tests of Particulate matter, Extractable volume and Description.Description | CDL, KolkataCDSCO lab | Jan 2026 |
| Buprenorphine Injection I.P. (Talgesic Injection) | BUP324002Mfg 2024-06 · Exp 2026-05 | Spurious Identification and Assay of Buprenorphine Hydrochloride, Particulate matter and DescriptionAssay | CDL, KolkataCDSCO lab | May 2025 |
Batches reported as suspected spurious under this label
CDSCO's spurious-drug alerts list batches that purport to be made by a company but are suspected counterfeits. The labelled manufacturer's reply is shown where CDSCO published it.
| Product | Batch | Reported by | Firm's reply | Alert |
|---|---|---|---|---|
| Deflazacort Tablets 6 mg Defcort 6 | 13240334A | RDTL, Chandigarh | The actual manufacturer (as per label claim) has informed that the impugned batch of the product has not been manufactured by them and that it is a spurious drug. | Dec 2025 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.